Your group chat has a new herb, and for once it has a study attached. Shatavari is the Ayurvedic root that has been showing up in 'women's balance' bottles for years, usually without a dose and always without receipts. In August 2026 that changed: a randomized, double-blind, placebo-controlled trial reported real numbers in perimenopausal women Established: International Journal of Women's Health.

Here is what the study actually says, what the coverage left out, and how to read the bottles that are about to appear in your feed.

The study in one paragraph

Eighty perimenopausal women aged 40 to 55 in India were randomly assigned to 300 mg per day of a standardized shatavari root extract (branded SRI-81, made by Ixoreal Biomed) or a placebo for eight weeks Established: International Journal of Women's Health. Of the 73 who finished:

  • Total Menopause Rating Scale scores fell 42.6% from baseline in the shatavari group, versus 5.5% in the placebo group.
  • Perceived stress scores dropped about 30% from baseline.
  • Hot-flash scores fell 26%, versus 7% with placebo.
  • Fatigue and vigor measures also improved.
  • No adverse events were reported, and liver and kidney function markers stayed stable across the eight weeks.

The MRS is a self-reported symptom scale covering hot flashes, sleep problems, joint and muscle pain, mood, irritability, anxiety, fatigue, bladder issues, and vaginal dryness Established: International Journal of Women's Health. So the claim is specific and real: the women who took the extract reported fewer and lighter symptoms than the women who took the placebo. That is the whole claim, and it is a decent one.

What the numbers do not mean

Before the bottle goes in your cart, sit with the parts the headlines skip.

One trial, one country, one manufacturer's ingredient. This is a single RCT, run at two Indian hospitals, on an ingredient made by the company whose CEO is quoted celebrating the results in the trade press Press: NutraIngredients. That does not make the data fake. It makes it the first chapter, not the conclusion. Replication in other populations and sites, ideally by independent researchers, is what moves a finding from promising to established. Watch for that, not for more press releases.

Self-reported scales, not blood tests. Every headline outcome here is a questionnaire. The study does not establish what shatavari does to hormone levels in a perimenopausal body, and the phytoestrogen story is a hypothesis about shatavarin compounds, not something this trial tested Press: NutraIngredients. If your friend tells you it 'rebalances hormones,' that is marketing wearing a lab coat. The supplement aisle has a test for this kind of claim, and it is not another review (the label-vs-blood-test explainer).

Not a comparison against HRT. There was no hormone-therapy arm in the trial. A botanical with one eight-week study is not evidence-equivalent to treatments with decades of randomized data behind them. If your symptoms are moderate or severe, or they are wrecking your sleep, this study does not change the medical conversation; it adds a low-stakes option to it.

Eight weeks is a snapshot. The trial shows short-term tolerability in 73 women: no adverse events, stable liver and kidney markers. It does not tell you what a year of daily use does, and it does not tell you how the herb interacts with your actual medication list. The Health Canada license for SRI-81 (NPN 80149608, July 2026) approves claims about menopausal symptoms, hot flashes and night sweats, and mild anxiety and fatigue, which is a real regulatory step and still a monograph-based authorization, not a guarantee Press: NutraIngredients.

The label-reading checklist

If you decide to try it, the bottle has to survive five questions:

  1. Standardized extract, named. The study used SRI-81, standardized to Shatavarin IV and total shatavarins Press: NutraIngredients. A bottle that says 'shatavari' with no standardization story is a different product from the one studied.
  2. The studied dose. 300 mg per day. If the label does not state a dose per ingredient, you cannot test what the label refuses to measure, and that is the shell-game tell this site keeps flagging.
  3. Root extract. The trial used root extract, not the whole plant and not a proprietary blend.
  4. No mystery formulas. If shatavari is buried in a 12-herb 'women's vitality' blend with no individual doses, the study does not apply to that bottle. The single ingredient at a stated dose is the one with evidence.
  5. Regulatory markers. Canadian products can carry the Health Canada NPN; elsewhere, third-party testing seals are a reasonable bonus, not proof of efficacy.

Wait for replication, or try it?

The honest split, no cheerleading:

Try it, as an experiment, if: your symptoms are mild, the label passes all five questions above, you have no liver or kidney conditions, you are not stacking it with other botanicals, and you have told your clinician. Run it for eight weeks with a symptom journal, and stop if nothing moves or anything feels off. The studied dose has short-term tolerability data, which is more than almost anything else in the supplement aisle can say.

Wait, or see a clinician instead, if: your flashes are frequent enough to disrupt sleep or work, you are on medications (especially anything processed by the liver), you have liver or kidney disease, or you are hoping for hormone-therapy-level results. A single RCT is not the answer to moderate or severe symptoms; the evidence-backed options are. (Shatavari supplements on Amazon, if you want to see what is actually on the shelf and read the labels before you buy)

The bottom line

Shatavari is now the best-evidenced named botanical in the perimenopause supplement aisle, and that is a lower bar than it sounds like. One decent trial is promising, not proven. Buy the standardized extract at the studied dose, treat it as an experiment rather than a prescription, and let replication do the convincing. The study gave us receipts. The bottles still owe us the proof.